JAK Inhibitors Video Perspectives

In this video, Laura C. Cappelli, MD, assistant professor of medicine at Johns Hopkins University School of Medicine, discussed:

• recent advances in rheumatoid arthritis treatment, including FDA approval of two JAK inhibitors: baricitinib (Olumiant; Eli Lilly) and upadacitinib (Rinvoq; AbbVie);
• exercise and mindfulness as adjuncts to therapy in RA;
• the importance of taking care of patients’ comorbidities and any side effects from RA medication;
• differences between JAK inhibitors and biologics;
• safety concerns of JAK inhibitors;
• making sure patients with long-standing RA have treatment options;
• the efficacy of JAK inhibitors in dermatologic diseases, like psoriatic arthritis;
• considerations for patients nonresponsive to RA treatment; and
• the need for novel agents with different mechanisms of action and targeted treatments for RA, as well as the importance of nonmedication options as adjuncts to improve quality of life.